Articles

Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne muscular dystrophy drug, but analysts worry it will take time for patients and doctors to feel safe using it.

Instead of relying on data points to decode Gen Z — or, really, anyone starting their financial journey — I want to speak directly to them.

Procter & Gamble Co. on Tuesday said it would raise prices on around 25% of the products it sells in the U.S. due to tariffs. But as higher prices keep shoppers cautious, executives at the maker of consumer products including Tide and Bounty argued that cheaper products don’t guarantee longer-term success.

Here’s how to read the second-quarter report on gross domestic product.

A Bernstein analyst says Comcast executives will need to address their efforts to stabilize the broadband subscriber base and whether these are showing initial success.

Trade deals like the U.S.-European Union agreement could be at risk from a case winding its way through courts in the U.S.

The stock market is more overvalued than at almost any time in U.S. history.

These are not “normal times” when it comes to the Federal Reserve and monetary policy.

The chip company is waiting to sell its H20 chips in China again, which a Mizuho analyst said will help the case for its earnings per share to reach $7 next fiscal year.

While investors today seem gripped by a mania for growth stocks, they are really just gripped by momentum. They are buying assets that have already gone up in the hope that they will keep going up.

“Consumers are rattled,” one analyst noted, “and rattled consumers spend less than confident consumers.”

Job openings fell in June to close to a postpandemic low as trade wars discouraged businesses from hiring, but the rate of layoffs also stood near a record low, in a good sign for the broader U.S. economy.